BioCentury
ARTICLE | Company News

GNS, Amgen to use AI to explore patient response to mCRC drug Vectibix

September 14, 2018 3:18 PM UTC

GNS Healthcare Inc. (Cambridge, Mass), Amgen Inc. (NASDAQ:AMGN) and the Alliance for Clinical Trials in Oncology (Boston, Mass.) partnered to use artificial intelligence to identify factors that drive and predict patient responses to Amgen’s metastatic colorectal cancer (mCRC) Vectibix panitumumab.

GNS will use its AI platform Reverse Engineering & Forward Simulation (REFS) to create causal models using combined data from Amgen's Phase II PEAK trial and the alliance's Phase III CALGB 80405 trial...